Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Head and Neck Cancer

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 330 articles:
HTML format



Single Articles


    April 2024
  1. CHOW JCH, Lee J, Lai MMP, Li S, et al
    Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study.
    Radiother Oncol. 2024;193:110143.
    PubMed     Abstract available


  2. ZARINSHENAS R, Campbell P, Sun K, Molitoris JK, et al
    Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric modulated arc therapy and pencil beam scanning proton therapy.
    Radiother Oncol. 2024;193:110112.
    PubMed     Abstract available


  3. ORLANDI E, Fontana G, Licitra L, Tinelli C, et al
    Comprehensive insights on the underlying potential and advantage of proton therapy over intensity-modulated photon radiation therapy as highlighted in a wide real world data analysis.
    Radiother Oncol. 2024;193:110122.
    PubMed    


    March 2024
  4. BERTHOLET J, Mackeprang PH, Loebner HA, Mueller S, et al
    Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
    Radiother Oncol. 2024 Mar 19:110237. doi: 10.1016/j.radonc.2024.110237.
    PubMed     Abstract available


  5. BOON CS, Ramkumar S, Boon IS
    Proton beam radiotherapy head and neck cancer study design and endpoints.
    Radiother Oncol. 2024 Mar 16:110234. doi: 10.1016/j.radonc.2024.110234.
    PubMed    


  6. KOUTROUMPAKIS E, Mohamed ASR, Chaftari P, Rosenthal DI, et al
    Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study.
    Radiother Oncol. 2024 Mar 9:110220. doi: 10.1016/j.radonc.2024.110220.
    PubMed     Abstract available


  7. CHOW JCH, Ho JCS, Man Cheung K, Johnson D, et al
    Neurological complications of modern radiotherapy for head and neck cancer.
    Radiother Oncol. 2024 Mar 2:110200. doi: 10.1016/j.radonc.2024.110200.
    PubMed     Abstract available


  8. CARSUZAA F, Chary E, Thariat J, Dufour X, et al
    Obstructive sleep apnea syndrome: A frequent and difficult-to-detect complication of radiotherapy for oropharyngeal cancers.
    Radiother Oncol. 2024;192:110109.
    PubMed     Abstract available


  9. ZHANG WW, Lin JY, Wang GY, Huang CL, et al
    Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Radiother Oncol. 2024;194:110189.
    PubMed     Abstract available


    February 2024
  10. POPULAIRE P, Defraene G, Haustermans K
    Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 28:110175. doi: 10.1016/j.radonc.2024.110175.
    PubMed    


  11. KOTO M, Ikawa H, Inaniwa T, Imai R, et al
    Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.
    Radiother Oncol. 2024;194:110180.
    PubMed     Abstract available


  12. BERBEE M, Muijs CT, Schuit E
    Response to letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 17:110176. doi: 10.1016/j.radonc.2024.110176.
    PubMed    


  13. FIORINO C, Palumbo D, Mori M, Palazzo G, et al
    Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial.
    Radiother Oncol. 2024;194:110160.
    PubMed     Abstract available


  14. WANG X, Huang N, Yip PL, Wang J, et al
    The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-word study with a large population.
    Radiother Oncol. 2024;194:110154.
    PubMed     Abstract available


  15. HORSHOLT KRISTENSEN M, Kristina Sorensen M, Tramm T, Alsner J, et al
    Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - a DAHANCA 19 study.
    Radiother Oncol. 2024 Feb 8:110149. doi: 10.1016/j.radonc.2024.110149.
    PubMed     Abstract available


  16. PERRIER L, Balusson F, Morelle M, Castelli J, et al
    Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
    Radiother Oncol. 2024;193:110116.
    PubMed     Abstract available


  17. LINGE A, Patil S, Grosser M, Lohaus F, et al
    The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
    Radiother Oncol. 2024;191:110055.
    PubMed     Abstract available


    January 2024
  18. FRANK MH, van Dijk BAC, Schoonbeek RC, Zindler J, et al
    Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort.
    Radiother Oncol. 2024 Jan 21:110107. doi: 10.1016/j.radonc.2024.110107.
    PubMed     Abstract available


  19. BLITZER GC, Paz C, Glassey A, Ganz OR, et al
    Functionality of Bone Marrow Mesenchymal Stromal Cells Derived from Head and Neck Cancer Patients - A FDA-IND Enabling Study Regarding MSC-based Treatments for Radiation-Induced Xerostomia.
    Radiother Oncol. 2024 Jan 13:110093. doi: 10.1016/j.radonc.2024.110093.
    PubMed     Abstract available


  20. PIERIK AS, Poell JB, Brink A, Stigter-van Walsum M, et al
    Intratumor genetic heterogeneity and head and neck cancer relapse.
    Radiother Oncol. 2024 Jan 5:110087. doi: 10.1016/j.radonc.2024.110087.
    PubMed     Abstract available


  21. WANG F, Zhou L, Zhang LJ, Xie CB, et al
    Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: a propensity score-matched cohort study.
    Radiother Oncol. 2024 Jan 5:110081. doi: 10.1016/j.radonc.2024.110081.
    PubMed     Abstract available


  22. GUO Q, Lu T, Huang W, Xu H, et al
    Selectively sparing of the supraclavicular area during intensity-modulated radiotherapy in nasopharyngeal carcinoma: A double-center observation study.
    Radiother Oncol. 2024 Jan 4:110086. doi: 10.1016/j.radonc.2024.110086.
    PubMed     Abstract available


  23. ZHONG Y, Lyu X, Huang M, Zheng L, et al
    Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer.
    Radiother Oncol. 2024;190:110022.
    PubMed     Abstract available


  24. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
    Response to the letter-to-the-editor "Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110036.
    PubMed    


  25. SOMAY E, Yilmaz B, Topkan E
    Comments on "Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110035.
    PubMed    


  26. ZHU Y, Cheng J, Li Y, Pan D, et al
    Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.
    Radiother Oncol. 2024;190:110033.
    PubMed     Abstract available


  27. LIMKIN E, Blanchard P, Lacas B, Bourhis J, et al
    Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.
    Radiother Oncol. 2024;190:110011.
    PubMed     Abstract available


  28. RONCHI S, Cicchetti A, Bonora M, Ingargiola R, et al
    Curative carbon ion radiotherapy in a head and neck mucosal melanoma series: Facing the future within multidisciplinarity.
    Radiother Oncol. 2024;190:110003.
    PubMed     Abstract available


  29. MUMAW DA, Hazy AJ, Vayntraub A, Quinn TJ, et al
    Low contralateral failure rate with unilateral proton beam radiotherapy for oropharyngeal squamous cell carcinoma: A multi-institutional prospective study from the proton collaborative group.
    Radiother Oncol. 2024;190:109977.
    PubMed     Abstract available


    December 2023
  30. MURDAUGH DL, Milner D, Cardenas CE, Heinzman KA, et al
    Volumetric Brain Assessment of Long-Term Head and Neck Cancer Survivors.
    Radiother Oncol. 2023 Dec 22:110068. doi: 10.1016/j.radonc.2023.110068.
    PubMed     Abstract available


  31. LIN CY, Chang CL, Lin KC, Chen WM, et al
    Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 Dec 22:110067. doi: 10.1016/j.radonc.2023.110067.
    PubMed     Abstract available


  32. YU-CHEN, Luo MJ, Liu RP, Jin J, et al
    Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 20:110051. doi: 10.1016/j.radonc.2023.110051.
    PubMed     Abstract available


  33. AI QYH, King AD, Yuan H, Vardhanabhuti V, et al
    Radiologic extranodal extension for nodal staging in nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 13:110050. doi: 10.1016/j.radonc.2023.110050.
    PubMed     Abstract available


  34. BIRD D, Speight R, Andersson S, Wingqvist J, et al
    Deep learning MRI-only synthetic-CT generation for pelvis, brain and head and neck cancers.
    Radiother Oncol. 2023 Dec 12:110052. doi: 10.1016/j.radonc.2023.110052.
    PubMed     Abstract available


  35. HABRICH J, Boeke S, Fritz V, Koerner E, et al
    Reproducibility of diffusion-weighted magnetic resonance imaging in head and neck cancer assessed on a 1.5 T MR-Linac and comparison to parallel measurements on a 3 T diagnostic scanner.
    Radiother Oncol. 2023 Dec 7:110046. doi: 10.1016/j.radonc.2023.110046.
    PubMed     Abstract available


  36. MARIA HUYNH TT, Dale E, Sorum Falk R, Paulsen Hellebust T, et al
    Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters.
    Radiother Oncol. 2023 Dec 5:110044. doi: 10.1016/j.radonc.2023.110044.
    PubMed     Abstract available


  37. MISZCZYK M, Suleja A, Sobel S, Stec M, et al
    Salvage re-irradiation in non-melanoma skin cancers: A multicenter analysis.
    Radiother Oncol. 2023;189:109945.
    PubMed     Abstract available


  38. HOU Z, Guo Y, Shen X, Dong B, et al
    Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study.
    Radiother Oncol. 2023;189:109937.
    PubMed     Abstract available


  39. TSAI MH, Chang JTC, Lu HH, Wu YH, et al
    Development and validation of a machine learning model of radiation-induced hypothyroidism with clinical and dose-volume features.
    Radiother Oncol. 2023;189:109911.
    PubMed     Abstract available


    November 2023
  40. MENG Z, Li P, Yang D, Huang H, et al
    The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
    Radiother Oncol. 2023 Nov 24:110027. doi: 10.1016/j.radonc.2023.110027.
    PubMed     Abstract available


  41. SOMAY E, Topkan E, Selek U
    Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110025. doi: 10.1016/j.radonc.2023.110025.
    PubMed    


  42. BUURMAN DJM, Speksnijder CM, Granzier ME, Timmer VCML, et al
    Response to: Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110026. doi: 10.1016/j.radonc.2023.110026.
    PubMed    


  43. DELERUE C, Pasquier D, Bogart E, Mirabel X, et al
    Stereotactic reirradiation in the treatment of head and neck cancers: A retrospective study on the long-term experience of the Oscar Lambret Center.
    Radiother Oncol. 2023;190:110029.
    PubMed     Abstract available


  44. HUANG CL, Wang GY, Lou JH, Chen L, et al
    Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up.
    Radiother Oncol. 2023;190:110032.
    PubMed     Abstract available


  45. BERBEE M, Muijs CT, Voncken FEM, Wee LS, et al
    External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts.
    Radiother Oncol. 2023 Nov 8:109979. doi: 10.1016/j.radonc.2023.109979.
    PubMed     Abstract available


  46. HR M, P P, L H, Ds M, et al
    PROton versus photon Therapy for Esophageal Cancer - a Trimodality strategy (PROTECT) NCT050555648.
    Radiother Oncol. 2023 Nov 5:109980. doi: 10.1016/j.radonc.2023.109980.
    PubMed    


  47. CHEN L, Li J, Li K, Hu J, et al
    Evaluation and Analysis of Risk Factors of Hearing Impairment for Nasopharyngeal Carcinoma treated using Intensity-Modulated Radiotherapy.
    Radiother Oncol. 2023 Nov 3:109985. doi: 10.1016/j.radonc.2023.109985.
    PubMed     Abstract available


  48. KIM K, Oh D, Myoung Noh J, Won Min Y, et al
    Outcomes Following Hypofractionated Radiation Therapy Alone for Surgically Unfit Early Esophageal Squamous Cell Carcinoma Patients; A Retrospective Single Center Analysis.
    Radiother Oncol. 2023 Nov 3:109982. doi: 10.1016/j.radonc.2023.109982.
    PubMed     Abstract available


    October 2023
  49. HE YQ, Wang TM, Yang DW, Xue WQ, et al
    A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 30:109974. doi: 10.1016/j.radonc.2023.109974.
    PubMed     Abstract available


  50. AMSTUTZ F, Krcek R, Bachtiary B, Weber DC, et al
    Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - from a fixed beam line to an arc.
    Radiother Oncol. 2023 Oct 30:109973. doi: 10.1016/j.radonc.2023.109973.
    PubMed     Abstract available


  51. FRIBORG J, Jensen K, Eriksen JG, Samsoe E, et al
    Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer.
    Radiother Oncol. 2023 Oct 21:109958. doi: 10.1016/j.radonc.2023.109958.
    PubMed     Abstract available


  52. CHEN AM
    Management of Unknown Primary Head and Neck Cancer with Radiation Therapy in the Era of Human Papillomavirus (HPV): No Longer Cutting Down the Tree to Get an Apple.
    Radiother Oncol. 2023 Oct 14:109952. doi: 10.1016/j.radonc.2023.109952.
    PubMed     Abstract available


  53. GAI X, Su L, Huang S, Zeng J, et al
    Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 7:109942. doi: 10.1016/j.radonc.2023.109942.
    PubMed     Abstract available


  54. LI S, Zhang W, Liang B, Huang W, et al
    A Rulefit-Based Prognostic Analysis Using Structured MRI Report to Select Potential Beneficiaries from Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Dual-Centre Study.
    Radiother Oncol. 2023 Oct 7:109943. doi: 10.1016/j.radonc.2023.109943.
    PubMed     Abstract available


  55. LIN CH, Yan JL, Yap WK, Kang CJ, et al
    Prognostic Value of Interim CT-based Peritumoral and Intratumoral Radiomics in Laryngeal and Hypopharyngeal Cancer Patients Undergoing Definitive Radiotherapy.
    Radiother Oncol. 2023 Oct 6:109938. doi: 10.1016/j.radonc.2023.109938.
    PubMed     Abstract available


  56. SUN XS, Wang JW, Han F, Zou RH, et al
    Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort study.
    Radiother Oncol. 2023 Oct 6:109939. doi: 10.1016/j.radonc.2023.109939.
    PubMed     Abstract available


  57. AHERN V, Adeberg S, Fossati P, Garrett R, et al
    An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia.
    Radiother Oncol. 2023;187:109816.
    PubMed     Abstract available


    September 2023
  58. YEONG SONG J, Sung Ho M, Suh YG, Kim JH, et al
    Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: a multicenter retrospective study (KROG 21-10).
    Radiother Oncol. 2023 Sep 30:109936. doi: 10.1016/j.radonc.2023.109936.
    PubMed     Abstract available


  59. BOLLEN H, Gulyban A, Nuyts S
    Impact of consensus guidelines on delineation of primary tumor Clinical Target Volume (CTVp) for head and neck cancer: results of a national review project.
    Radiother Oncol. 2023 Sep 20:109915. doi: 10.1016/j.radonc.2023.109915.
    PubMed     Abstract available


  60. LIU S, Zou Y, Zhong M, Li T, et al
    Prognostic Significance of MRI-Defined Sarcopenia in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matched Analysis of Real-World Data.
    Radiother Oncol. 2023 Sep 5:109904. doi: 10.1016/j.radonc.2023.109904.
    PubMed     Abstract available


  61. YAN W, Liu T, He M, Yi J, et al
    Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.
    Radiother Oncol. 2023 Sep 5:109903. doi: 10.1016/j.radonc.2023.109903.
    PubMed     Abstract available


  62. ADRIAN G, Forslund O, Pedersen L, Sjovall J, et al
    Circulating tumour HPV16 DNA quantification - A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy.
    Radiother Oncol. 2023;186:109773.
    PubMed     Abstract available


  63. MCSWEENEY DM, Raby S, Radhakrishna G, Weaver J, et al
    Low muscle mass measured at T12 is a prognostic biomarker in unresectable oesophageal cancers receiving chemoradiotherapy.
    Radiother Oncol. 2023;186:109764.
    PubMed     Abstract available


  64. TRADA Y, Lee MT, Jameson MG, Chlap P, et al
    Mid-treatment 18F-FDG PET imaging changes in parotid gland correlates to radiation-induced xerostomia.
    Radiother Oncol. 2023;186:109745.
    PubMed     Abstract available


  65. SIJTSEMA ND, Verduijn GM, Nasserinejad K, van Norden Y, et al
    Development of a local dose-response relationship for osteoradionecrosis within the mandible.
    Radiother Oncol. 2023;186:109736.
    PubMed     Abstract available


  66. LI D, Yang LN, Lin JY, Wu YZ, et al
    Eosinophil Dynamics During Chemo-Radiotherapy Correlate to Clinical Outcome in Stage ?-?a Nasopharyngeal Carcinoma Patients: Results from A Large Cohort Study.
    Radiother Oncol. 2023 Sep 1:109900. doi: 10.1016/j.radonc.2023.109900.
    PubMed     Abstract available


    August 2023
  67. OZER O, Shafi H, O'Reilly D, Loiseau C, et al
    Need for standardization in the use of structures in the intensity-modulated radiation therapy planning of head and neck cancers, a GORTEC study.
    Radiother Oncol. 2023 Aug 31:109895. doi: 10.1016/j.radonc.2023.109895.
    PubMed     Abstract available


  68. DING X, Cui X, Cui X, Wang S, et al
    Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: a meta-analysis.
    Radiother Oncol. 2023 Aug 23:109860. doi: 10.1016/j.radonc.2023.109860.
    PubMed     Abstract available


  69. ROESCH J, Ruhle A, Nicolay NH, Hecht M, et al
    Reply to the comment on "Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis'' by Kahvecioglu et al.
    Radiother Oncol. 2023 Aug 22:109866. doi: 10.1016/j.radonc.2023.109866.
    PubMed    


  70. IYIZOBA-EBOZUE Z, Prestwich R, Brown S, Hall E, et al
    Neurocognitive function following (chemo)radiotherapy for nasopharyngeal cancer and other head and neck cancers: a systematic review.
    Radiother Oncol. 2023 Aug 22:109863. doi: 10.1016/j.radonc.2023.109863.
    PubMed     Abstract available


  71. KATSUTA T, Murakami Y, Kawahara D, Miyoshi S, et al
    Novel Simulation for Dosimetry Impact of Diaphragm Respiratory Motion in Four-Dimensional Volumetric Modulated Arc Therapy for Esophageal Cancer.
    Radiother Oncol. 2023 Aug 8:109849. doi: 10.1016/j.radonc.2023.109849.
    PubMed     Abstract available


  72. BUURMAN DJM, Speksnijder CM, Granzier ME, C M L Timmer V, et al
    The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Aug 3:109847. doi: 10.1016/j.radonc.2023.109847.
    PubMed     Abstract available


  73. KOTEVSKI DP, Vajdic CM, Field M, Smee RI, et al
    Inter-hospital variation in data collection, radiotherapy treatment, and survival in patients with head and neck cancer: a multisite study.
    Radiother Oncol. 2023 Aug 3:109843. doi: 10.1016/j.radonc.2023.109843.
    PubMed     Abstract available


  74. DIAS GOMES DA SILVA N, Sergio da Silva Santos P, Carolina Magalhaes A, Afonso Rabelo Buzalaf M, et al
    Antibacterial, antibiofilm and anticaries effect of BioXtra(R) mouthrinse for head and neck cancer (HNC) patients under a microcosm biofilm model.
    Radiother Oncol. 2023 Aug 3:109846. doi: 10.1016/j.radonc.2023.109846.
    PubMed     Abstract available


    July 2023
  75. LIU J, Zhang B, Su Y, Qin G, et al
    Hypofractionated Radiotherapy compared with Conventionally Fractionated Radiotherapy to treat Initial Distant Metastases in Nasopharyngeal Carcinoma: A Multicenter, prospective, randomized, Phase II Trial.
    Radiother Oncol. 2023 Jul 20:109815. doi: 10.1016/j.radonc.2023.109815.
    PubMed     Abstract available


  76. HANSEN CR, Jensen K, Smulders B, Holm AIS, et al
    Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35.
    Radiother Oncol. 2023 Jul 19:109812. doi: 10.1016/j.radonc.2023.109812.
    PubMed     Abstract available


  77. KAHVECIOGLU A, Yuce Sari S, Yazici G
    Comments on ''Dose-escalated Re-irradiation Improves Outcome in Locally Recurrent Head and Neck Cancer - Results of a Large Multicenter Analysis''.
    Radiother Oncol. 2023 Jul 17:109809. doi: 10.1016/j.radonc.2023.109809.
    PubMed    


  78. LIN C, Lu N, Liang JL, Guo J, et al
    Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jul 7:109802. doi: 10.1016/j.radonc.2023.109802.
    PubMed     Abstract available


  79. WEISS Y, Chin L, Younas E, Guo K, et al
    Cine MRI-based Analysis of Intrafractional Motion in Radiation Treatment Planning of Head and Neck Cancer Patients.
    Radiother Oncol. 2023 Jul 4:109790. doi: 10.1016/j.radonc.2023.109790.
    PubMed     Abstract available


  80. LIN P, Holloway L, Min M, Lee M, et al
    Prognostic and predictive values of baseline and mid-treatment FDG-PET in oropharyngeal carcinoma treated with primary definitive (chemo)radiation and impact of HPV status: Review of current literature and emerging roles.
    Radiother Oncol. 2023;184:109686.
    PubMed     Abstract available


  81. DE JONG BA, Korevaar EW, Maring A, Werkman CI, et al
    Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic.
    Radiother Oncol. 2023;184:109670.
    PubMed     Abstract available


  82. ZHOU J, Wu J, Wu G, Huang J, et al
    TBX18 knockdown sensitizes esophageal squamous cell carcinoma to radiotherapy by blocking the CHN1/RhoA axis.
    Radiother Oncol. 2023 Jul 1:109788. doi: 10.1016/j.radonc.2023.109788.
    PubMed     Abstract available


    June 2023
  83. KJEMS J, Elisabet Hakansson K, Andrup Kristensen C, Grau Eriksen J, et al
    The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas.
    Radiother Oncol. 2023 Jun 27:109771. doi: 10.1016/j.radonc.2023.109771.
    PubMed     Abstract available


  84. LIN X, Guo Z, Lin S, Qiu Y, et al
    Transcriptional expression of radiation-induced early cortical morphological alterations and its association with radiation necrosis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jun 27:109770. doi: 10.1016/j.radonc.2023.109770.
    PubMed     Abstract available


  85. GAN Y, Langendijk JA, van der Schaaf A, van den Bosch L, et al
    An efficient strategy to select head and neck cancer patients for adaptive radiotherapy.
    Radiother Oncol. 2023 Jun 21:109763. doi: 10.1016/j.radonc.2023.109763.
    PubMed     Abstract available


  86. YANG Q, Xia L, Feng LF, Gong WJ, et al
    Multi-trajectories of health-related quality of life and their associated factors in patients with nasopharyngeal carcinoma: A longitudinal study.
    Radiother Oncol. 2023 Jun 12:109743. doi: 10.1016/j.radonc.2023.109743.
    PubMed     Abstract available


  87. ROJO-SANTIAGO J, Korevaar E, Perko Z, Both S, et al
    PTV-based VMAT vs. robust IMPT for Head-and-Neck Cancer: A probabilistic uncertainty analysis of clinical plan evaluation with the Dutch model-based selection.
    Radiother Oncol. 2023 Jun 8:109729. doi: 10.1016/j.radonc.2023.109729.
    PubMed    


  88. CAMPO F, Iocca O, De Virgilio A, Mazzola F, et al
    Treatment of oropharyngeal squamous cell carcinoma: Is swallowing quality better after TORS or RT?
    Radiother Oncol. 2023;183:109547.
    PubMed     Abstract available


  89. PARK JB, Wu HG, Kim JH, Lee JH, et al
    Adjuvant radiotherapy in node-negative salivary malignancies of the parotid gland: A multi-institutional analysis.
    Radiother Oncol. 2023;183:109554.
    PubMed     Abstract available


    May 2023
  90. KONG FF, Pan GS, Du CR, Ni MS, et al
    Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis.
    Radiother Oncol. 2023 May 25:109721. doi: 10.1016/j.radonc.2023.109721.
    PubMed     Abstract available


  91. MCDONALD BA, Salzillo T, Mulder S, Ahmed S, et al
    Prospective Evaluation of In Vivo and Phantom Repeatability and Reproducibility of Diffusion-Weighted MRI Sequences on 1.5T MRI-Linear Accelerator (MR-Linac) and MR Simulator Devices for Head and Neck Cancers.
    Radiother Oncol. 2023 May 19:109717. doi: 10.1016/j.radonc.2023.109717.
    PubMed     Abstract available


  92. LU T, Xu H, Huang W, Zong J, et al
    Constructing an Individualized Surveillance Framework for Nasopharyngeal Carcinoma Based on a Dynamic Risk-adapted Approach.
    Radiother Oncol. 2023 May 17:109716. doi: 10.1016/j.radonc.2023.109716.
    PubMed     Abstract available


  93. MORAL NAKAMURA D, da Graca Pinto H, Baena Elchin C, Thomazotti Berard L, et al
    Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 17:109715. doi: 10.1016/j.radonc.2023.109715.
    PubMed     Abstract available


  94. LU J, Qin Z, Li N, Ma J, et al
    High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 9:109700. doi: 10.1016/j.radonc.2023.109700.
    PubMed     Abstract available


  95. FENG ZONG J, Lin PJ, Tsou HH, Guo Q, et al
    Comparison the Acute Toxicity of Two Different Induction Chemotherapy Schedules with Cisplatin and Fluorouracil in Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 May 9:109699. doi: 10.1016/j.radonc.2023.109699.
    PubMed     Abstract available


    April 2023
  96. ZHAO DW, Teng F, Meng LL, Fan WJ, et al
    Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2023 Apr 27:109683. doi: 10.1016/j.radonc.2023.109683.
    PubMed     Abstract available


  97. PAN Z, Men K, Liang B, Song Z, et al
    A subregion-based prediction model for local-regional recurrence risk in head and neck squamous cell carcinoma.
    Radiother Oncol. 2023 Apr 27:109684. doi: 10.1016/j.radonc.2023.109684.
    PubMed     Abstract available


  98. ZHAO W, Ke S, Cai X, Zuo Z, et al
    Radiotherapy plus camrelizumaband irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Radiother Oncol. 2023 Apr 25:109679. doi: 10.1016/j.radonc.2023.109679.
    PubMed     Abstract available


  99. A C FIAGAN Y, Bossuyt E, Nevens D, Machiels M, et al
    The use of in-vivo dosimetry to identify head and neck cancer patients needing adaptive radiotherapy.
    Radiother Oncol. 2023 Apr 19:109676. doi: 10.1016/j.radonc.2023.109676.
    PubMed     Abstract available


    March 2023
  100. BOLOGNA M, Corino V, Cavalieri S, Calareso G, et al
    Prognostic radiomic signature for head and neck cancer: development and validation on a multi-centric MRI dataset.
    Radiother Oncol. 2023 Mar 31:109638. doi: 10.1016/j.radonc.2023.109638.
    PubMed     Abstract available


  101. MENECEUR S, Lock S, Gudziol V, Hering S, et al
    Corrigendum to "Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens" [Radiother. Oncol. 137 (2019) 24-31].
    Radiother Oncol. 2023;183:109619.
    PubMed    


  102. S R MOHAMED A, Abusaif A, He R, Wahid K, et al
    Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study.
    Radiother Oncol. 2023 Mar 27:109641. doi: 10.1016/j.radonc.2023.109641.
    PubMed     Abstract available


  103. LU ZJ, Liu T, Lin JY, Pei ST, et al
    Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Mar 22:109635. doi: 10.1016/j.radonc.2023.109635.
    PubMed     Abstract available


  104. ALY F, Ronn Hansen C, Al Mouiee D, Sundaresan P, et al
    Outcome prediction models incorporating clinical variables for Head and Neck Squamous cell Carcinoma: a systematic review of methodological conduct and risk of bias.
    Radiother Oncol. 2023 Mar 17:109629. doi: 10.1016/j.radonc.2023.109629.
    PubMed    


  105. DUBEC MJ, Buckley DL, Berks M, Clough A, et al
    First-in-Human Technique Translation of Oxygen-Enhanced MRI to an MR Linac System in Patients with Head and Neck Cancer.
    Radiother Oncol. 2023 Mar 2:109592. doi: 10.1016/j.radonc.2023.109592.
    PubMed     Abstract available


  106. WU Z, Qi B, Lin FF, Zhang L, et al
    Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.
    Radiother Oncol. 2023 Mar 2:109595. doi: 10.1016/j.radonc.2023.109595.
    PubMed     Abstract available


  107. WANG JH, Salama V, McCoy L, Dede C, et al
    Dysphagia and shortness-of-breath as markers for treatment failure and survival in oropharyngeal cancer after radiation.
    Radiother Oncol. 2023;180:109465.
    PubMed     Abstract available


    February 2023
  108. TAN W, Mao M, He H, Chen M, et al
    Endonasopharyngeal Ultrasound and Magnetic Resonance Imaging Features of Recurrent Retropharyngeal Nodes in Nasopharyngeal Carcinoma Patients: A Radiologic-histopathologic Study.
    Radiother Oncol. 2023 Feb 24:109579. doi: 10.1016/j.radonc.2023.109579.
    PubMed     Abstract available


  109. BOLLEN H, Willems S, Wegge M, Maes F, et al
    Benefits of automated gross tumor volume segmentation in head and neck cancer using multi-modality information.
    Radiother Oncol. 2023 Feb 21:109574. doi: 10.1016/j.radonc.2023.109574.
    PubMed     Abstract available


  110. ZHANG J, Lam SK, Teng X, Ma Z, et al
    Radiomic Feature Repeatability and Its Impact on Prognostic Model Generalizability: A Multi-Institutional Study on Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 Feb 21:109578. doi: 10.1016/j.radonc.2023.109578.
    PubMed     Abstract available


  111. VALENTINI C, Ebert N, Koi L, Pfeifer M, et al
    Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
    Radiother Oncol. 2023 Feb 20:109546. doi: 10.1016/j.radonc.2023.109546.
    PubMed     Abstract available


  112. BEYAN C, Beyan E
    The prognosis may not be determined with the use of some pre-treatment complete blood count values in patients with non-metastatic nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Feb 9:109529. doi: 10.1016/j.radonc.2023.109529.
    PubMed    


  113. MAO JR, Lan KQ, Liu SL, Liu C, et al
    In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding ''Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?".
    Radiother Oncol. 2023 Feb 9:109530. doi: 10.1016/j.radonc.2023.109530.
    PubMed    


  114. PATRICIA KAPLAN L, Ivalu Sander Holm A, Grau Eriksen J, Heijmen BJM, et al
    Patient anatomy-specific trade-offs between sub-clinical disease coverage and normal tissue dose reduction in head-and-neck cancer.
    Radiother Oncol. 2023 Feb 8:109526. doi: 10.1016/j.radonc.2023.109526.
    PubMed     Abstract available


    January 2023
  115. YAO JJ, Jin YN, Zhang WJ, Zhang HY, et al
    Response to the letter by Dr Sari regarding the article "The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy".
    Radiother Oncol. 2023 Jan 31:109487. doi: 10.1016/j.radonc.2023.109487.
    PubMed    


  116. TERZIDIS E, Friborg J, Vogelius I, Lelkaitis G, et al
    Tumor volume definitions in head and neck squamous cell carcinoma - comparing PET/MRI and histopathology.
    Radiother Oncol. 2023 Jan 20:109484. doi: 10.1016/j.radonc.2023.109484.
    PubMed     Abstract available


  117. YE X, Liu J, Quan R, Lu Y, et al
    DKK1 Affects Survival of Patients with Head and Neck Squamous Cell Carcinoma by Inducing Resistance to Radiotherapy and Immunotherapy.
    Radiother Oncol. 2023 Jan 20:109485. doi: 10.1016/j.radonc.2023.109485.
    PubMed     Abstract available


  118. LUO X, Liao W, He Y, Tang F, et al
    Deep learning-based accurate delineation of primary gross tumor volume of nasopharyngeal carcinoma on heterogeneous magnetic resonance imaging: a large-scale and multi-center study.
    Radiother Oncol. 2023 Jan 16:109480. doi: 10.1016/j.radonc.2023.109480.
    PubMed     Abstract available


  119. WANG X, Bai H, Li R, Wang L, et al
    High versus Standard Radiation Dose of Definitive Concurrent Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Radiother Oncol. 2023 Jan 12:109463. doi: 10.1016/j.radonc.2023.109463.
    PubMed     Abstract available


  120. LI Y, Sijtsema NM, de Vette SPM, Steenbakkers RJHM, et al
    Validation of the (18)F-FDG PET image biomarker model predicting late xerostomia after head and neck cancer radiotherapy.
    Radiother Oncol. 2023 Jan 3:109458. doi: 10.1016/j.radonc.2022.109458.
    PubMed     Abstract available


  121. GUEVORGUIAN P, Chinnery T, Lang P, Nichols A, et al
    External validation of a CT-based radiomics signature in oropharyngeal cancer: Assessing sources of variation.
    Radiother Oncol. 2023;178:109434.
    PubMed     Abstract available


    December 2022
  122. LEEUWENBERG AM, Reitsma JB, Bosch LVD, Hoogland J, et al
    The relation between prediction model performance measures and patient selection outcomes for proton therapy in head and neck cancer.
    Radiother Oncol. 2022 Dec 22:109449. doi: 10.1016/j.radonc.2022.109449.
    PubMed     Abstract available


  123. HUANG X, Zhuang M, Yang S, Wang Y, et al
    The valuable role of dynamic (18)F FDG PET/CT-derived kinetic parameter K(i) in patients with nasopharyngeal carcinoma prior to radiotherapy: a prospective study.
    Radiother Oncol. 2022 Dec 22:109440. doi: 10.1016/j.radonc.2022.109440.
    PubMed     Abstract available


  124. MAO JR, Lan KQ, Liu SL, Liu C, et al
    Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?
    Radiother Oncol. 2022 Dec 22:109445. doi: 10.1016/j.radonc.2022.109445.
    PubMed     Abstract available


  125. LIU Y, Zhang Y, Wang J, Huang X, et al
    Caudal distribution pattern of metastatic neck lymph nodes in nasopharyngeal carcinoma and prognostic significance of nodal spread distances.
    Radiother Oncol. 2022 Dec 19:109443. doi: 10.1016/j.radonc.2022.109443.
    PubMed     Abstract available


  126. ZHU GL, Zhang XM, Yang KB, Tang LL, et al
    Metastatic patterns of level II-V cervical lymph nodes assessed per vertebral levels in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Dec 19:109447. doi: 10.1016/j.radonc.2022.109447.
    PubMed     Abstract available


  127. ZENG GP, Sun R, Zhao Z
    Letter to the editor regarding "The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: Significant acute and late toxicity reduction".
    Radiother Oncol. 2022 Dec 14:109442. doi: 10.1016/j.radonc.2022.109442.
    PubMed    


  128. HU YJ, Lu TZ, Guo QJ, Zhang L, et al
    The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2N1 nasopharyngeal carcinoma: a multicenter retrospective study.
    Radiother Oncol. 2022 Dec 1:S0167-8140(22)04582.
    PubMed     Abstract available


  129. VISSER S, O Ribeiro C, Dieters M, Mul VE, et al
    Robustness assessment of clinical adaptive proton and photon radiotherapy for oesophageal cancer in the model-based approach.
    Radiother Oncol. 2022;177:197-204.
    PubMed     Abstract available


  130. MOHAN V, Bruin NM, Steenbakkers RJHM, Noordzij W, et al
    Dose response modelling of secretory cell loss in salivary glands using PSMA PET.
    Radiother Oncol. 2022;177:164-171.
    PubMed     Abstract available


  131. MERLOTTI A, Alterio D, Orlandi E, Racadot S, et al
    AIRO GORTEC consensus on postoperative radiotherapy (PORT) in low-intermediate risk early stages oral squamous cell cancers (OSCC).
    Radiother Oncol. 2022;177:95-104.
    PubMed     Abstract available


  132. DE FELICE F, Cirillo A, Botticelli A
    Ideal regimen for induction chemotherapy in nasopharyngeal cancer: Still a hot issue?
    Radiother Oncol. 2022;177:111-112.
    PubMed    


  133. COSTEA M, Zlate A, Durand M, Baudier T, et al
    Comparison of atlas-based and deep learning methods for organs at risk delineation on head-and-neck CT images using an automated treatment planning system.
    Radiother Oncol. 2022;177:61-70.
    PubMed     Abstract available


    November 2022
  134. CHEN WY, Lu SH, Wang YM, Wang CW, et al
    Post-irradiation Sarcoma after Definitive Radiation Therapy for Nasopharyngeal Carcinoma.
    Radiother Oncol. 2022 Nov 23:S0167-8140(22)04560.
    PubMed     Abstract available


  135. LIU ZC, Zeng KH, Gu ZB, Chen RP, et al
    Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching.
    Radiother Oncol. 2022 Nov 18:S0167-8140(22)04554.
    PubMed     Abstract available


  136. WANG G, Huang C, Yang K, Guo R, et al
    Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04548.
    PubMed     Abstract available


  137. YAO JJ, Jin YN, Lin YJ, Zhang WJ, et al
    The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04547.
    PubMed     Abstract available


  138. BIN Y, Meng Z, Huang LL, Hu XY, et al
    Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04549.
    PubMed     Abstract available


  139. TAKADA A, Ichikawa Y, Nakamura S, Toyomasu Y, et al
    Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging.
    Radiother Oncol. 2022 Nov 10. pii: S0167-8140(22)04546.
    PubMed    


  140. ZHONG Z, Wang D, Liu Y, Shao S, et al
    Lymph Drainage and Cervical Fascia Anatomy-Oriented Differential Nodal CTV Delineation at the Supraclavicular Region for Esophageal Cancer and Nasopharyngeal Cancer.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04531.
    PubMed    


  141. CHOW JCH, Lui JCF, Cheung KM, Tam AHP, et al
    Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04529.
    PubMed     Abstract available


  142. HUANG H, Miao J, Zhao C, Wang L, et al
    Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing inten
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04517.
    PubMed    


  143. SARODE GS, Sarode SC, Anand R
    Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective pha
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04515.
    PubMed    


  144. LEE CT, Litwin S, Yao CMKL, Liu JC, et al
    Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints.
    Radiother Oncol. 2022;176:215-221.
    PubMed     Abstract available


    October 2022
  145. ROESCH J, Oertel M, Wegen S, Trommer M, et al
    Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
    Radiother Oncol. 2022 Oct 20. pii: S0167-8140(22)04502.
    PubMed     Abstract available


  146. TIEN CT, Chen CN, Young YH
    Post-irradiation endolymphatic hydrops vs. post-irradiation sudden deafness.
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04504.
    PubMed     Abstract available


  147. RONN HANSEN C, Price G, Field M, Sarup N, et al
    Larynx cancer survival model developed through open-source federated learning.
    Radiother Oncol. 2022 Oct 5. pii: S0167-8140(22)04493.
    PubMed     Abstract available


    September 2022
  148. NADERI E, Schack LMH, Welsh C, Sim AYL, et al
    Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer.
    Radiother Oncol. 2022 Sep 30. pii: S0167-8140(22)04486.
    PubMed     Abstract available


  149. HUMBERT-VIDAN L, Hansen CR, Fuller CD, Petit S, et al
    Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for Mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).
    Radiother Oncol. 2022 Sep 27. pii: S0167-8140(22)04473.
    PubMed    


  150. DRAGUET C, Barragan-Montero AM, Chocan Vera M, Thomas M, et al
    Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancer.
    Radiother Oncol. 2022 Sep 24. pii: S0167-8140(22)04263.
    PubMed     Abstract available


  151. OUD M, Breedveld S, Gizynska M, Kroesen M, et al
    An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer.
    Radiother Oncol. 2022 Sep 20. pii: S0167-8140(22)04278.
    PubMed     Abstract available


  152. TOPKAN E, Somay E, Yilmaz B
    In regard to recent published study of Massaccesi et al. titled 'A predictive nomogram for trismus after radiotherapy for head and neck cancer'. (Radiother Oncol. 2022 Jun 2: S0167-8140(22)04137-8. doi: 10.1016/j.radonc.2022.05.031).
    Radiother Oncol. 2022;174:132.
    PubMed    


  153. KOO J, Caudell JJ, Latifi K, Jordan P, et al
    Comparative evaluation of a prototype deep learning algorithm for autosegmentation of normal tissues in head and neck radiotherapy.
    Radiother Oncol. 2022;174:52-58.
    PubMed     Abstract available


    August 2022
  154. DE ROEST RH, van der Heijden M, W R Wesseling F, de Ruiter EJ, et al
    Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    Radiother Oncol. 2022 Aug 13. pii: S0167-8140(22)04234.
    PubMed     Abstract available


  155. ZHANG Y, Alshaikhi J, Amos RA, Lowe M, et al
    Improving workflow for adaptive proton therapy with predictive anatomical modelling: A proof of concept.
    Radiother Oncol. 2022;173:93-101.
    PubMed     Abstract available


    July 2022
  156. GHATASHEH H, Hui Huang S, Su J, Xu W, et al
    Evaluation of risk-tailored individualized selection of radiation therapy target volume for Head and Neck Carcinoma of Unknown Primary.
    Radiother Oncol. 2022 Jul 26. pii: S0167-8140(22)04214.
    PubMed     Abstract available


  157. HABRICH J, Boeke S, Nachbar M, Nikolaou K, et al
    Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac.
    Radiother Oncol. 2022 Jul 25. pii: S0167-8140(22)04218.
    PubMed     Abstract available


  158. HUANG H, Miao J, Xiao X, Hu J, et al
    Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): a prospective phase II randomized controlled study.
    Radiother Oncol. 2022 Jul 8. pii: S0167-8140(22)04191.
    PubMed     Abstract available


  159. PRICE JM, West CM, Dixon LM, Iyizoba-Ebozue Z, et al
    Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study.
    Radiother Oncol. 2022;172:111-117.
    PubMed     Abstract available


  160. WANG J, Liu Y, Shayan G, Ma Y, et al
    Lymph node ratio-dependent prognosis stratification and postoperative radiotherapy utilization in T1-2N1 oral cavity carcinoma.
    Radiother Oncol. 2022;172:83-90.
    PubMed     Abstract available


  161. NIU X, Liu P, Zhou X, Wang X, et al
    Is postoperative radiotherapy an essential treatment for nonmetastatic lymphoepithelial carcinoma of the salivary gland?
    Radiother Oncol. 2022;172:76-82.
    PubMed     Abstract available


  162. FRIED DV, Zhu T, Das SK, Shen C, et al
    Prospective assessment of sparing the parotid ducts via MRI sialography for reducing patient reported xerostomia.
    Radiother Oncol. 2022;172:42-49.
    PubMed     Abstract available


  163. HOFFMANN L, Mortensen H, Shamshad M, Berbee M, et al
    Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres.
    Radiother Oncol. 2022;172:32-41.
    PubMed     Abstract available


    June 2022
  164. QIAN D, Chen X, Shang X, Wang Y, et al
    Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II rando
    Radiother Oncol. 2022 Jun 25. pii: S0167-8140(22)04176.
    PubMed     Abstract available


  165. KROESE TE, Christ SM, van Rossum PSN, Burger MDL, et al
    Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.
    Radiother Oncol. 2022 Jun 23. pii: S0167-8140(22)04173.
    PubMed     Abstract available


  166. GONG J, Zhang W, Huang W, Liao Y, et al
    CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: a multicenter study.
    Radiother Oncol. 2022 Jun 21. pii: S0167-8140(22)04171.
    PubMed     Abstract available


  167. HANSEN CR, Price G, Field M, Sarup N, et al
    Open-source distributed learning validation for a larynx cancer survival model following radiotherapy.
    Radiother Oncol. 2022 Jun 20. pii: S0167-8140(22)04170.
    PubMed     Abstract available


  168. FU G, Xie Y, Pan J, Qiu Y, et al
    Longitudinal study of irradiation-induced brain functional network alterations in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Jun 16. pii: S0167-8140(22)04164.
    PubMed     Abstract available


  169. SCHOONBEEK RC, Festen S, van der Laan BFAM, Plaat BEC, et al
    The effect of delayed treatment initiation on adverse events and recurrence in older head and neck cancer patients.
    Radiother Oncol. 2022 Jun 6. pii: S0167-8140(22)04146.
    PubMed     Abstract available


  170. MASSACCESI M, Dinapoli N, Fuga V, Rupe C, et al
    A predictive nomogram for trismus after radiotherapy for head and neck cancer.
    Radiother Oncol. 2022 Jun 2. pii: S0167-8140(22)04137.
    PubMed     Abstract available


  171. PATIL S, Linge A, Grosser M, Lohaus F, et al
    Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
    Radiother Oncol. 2022;171:91-100.
    PubMed     Abstract available


    May 2022
  172. ZHAO DW, Fan WJ, Fang XM, Luo YR, et al
    Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Radiother Oncol. 2022 May 15. pii: S0167-8140(22)00251.
    PubMed     Abstract available


  173. YI-LIANG SHEN E, Hung TM, Tsan DL, Cheng NM, et al
    Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 May 11. pii: S0167-8140(22)00240.
    PubMed     Abstract available


  174. BIAU J, Nutting C, Langendijk JA, Frederic-Moreau T, et al
    Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers.
    Radiother Oncol. 2022;170:48-54.
    PubMed     Abstract available


  175. SOOKAROMDEE P, Wiwanitkit V
    Comment on "Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC".
    Radiother Oncol. 2022;170:250.
    PubMed    


  176. LOCK S, Baumann M
    Response to comment on "Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC".
    Radiother Oncol. 2022;170:251.
    PubMed    


  177. PERGOLIZZI S, Ferini G, Parisi S
    Letter to the editor of radiotherapy and oncology regarding of the paper "Stereotactic body radiotherapy for head and neck skin cancer" by IS Voruganti et al.
    Radiother Oncol. 2022;170:247.
    PubMed    


  178. KARAM I, Voruganti IS, Poon I
    Response letter to the Editor of Radiotherapy and Oncology regarding the paper "Stereotactic body radiotherapy for head and neck skin cancer" by IS Voruganti et al.
    Radiother Oncol. 2022;170:248-249.
    PubMed    


    April 2022
  179. ZHAO Y, Liao X, Wang Y, Lan W, et al
    Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy.
    Radiother Oncol. 2022 Apr 29. pii: S0167-8140(22)00232.
    PubMed     Abstract available


  180. DOHOPOLSKI M, Wang K, Morgan H, Sher D, et al
    Predicting the need for aggressive nutritional supplementation in head and neck cancer patients receiving radiation therapy.
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00224.
    PubMed     Abstract available


  181. SHEN H, Yin J, Niu R, Lian Y, et al
    Development and validation of a radiomic nomogram to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carc
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00222.
    PubMed     Abstract available


  182. LEE BM, Lee CG
    Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.
    Radiother Oncol. 2022 Apr 18. pii: S0167-8140(22)00191.
    PubMed     Abstract available


  183. WELZ S, Paulsen F, Pfannenberg C, Reimold M, et al
    Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [(18)F]FMISO PET/CT.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00170.
    PubMed     Abstract available


  184. JENSEN KH, Vogelius IR, Bernsdorf M, Gothelf A, et al
    Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00169.
    PubMed     Abstract available


  185. MULLER J, Leger S, Zwanenburg A, Suckert T, et al
    Radiomics-based tumor phenotype determination based on medical imaging and tumor microenvironment in a preclinical setting.
    Radiother Oncol. 2022;169:96-104.
    PubMed     Abstract available


  186. LOCK S, Linge A, Lohaus F, Ebert N, et al
    Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
    Radiother Oncol. 2022;169:8-14.
    PubMed     Abstract available


  187. ZHU J, Tan Y, Wang Q
    Letter to the editor regarding the article "Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis" by Chow et al.
    Radiother Oncol. 2022;169:152-153.
    PubMed    


  188. LUDWIG R, Hoffmann JM, Pouymayou B, Dappen MB, et al
    Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface.
    Radiother Oncol. 2022;169:1-7.
    PubMed     Abstract available


  189. KAO YS, Chen YF
    Comment to "Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis".
    Radiother Oncol. 2022;169:163.
    PubMed    


    March 2022
  190. YUE M, Xue X, Wang Z, Lambo RL, et al
    Dose prediction via distance-guided deep learning: initial development for nasopharyngeal carcinoma radiotherapy.
    Radiother Oncol. 2022 Mar 26. pii: S0167-8140(22)00150.
    PubMed     Abstract available


  191. BORDERIAS-VILLARROEL E, Taasti V, Van Elmpt W, Teruel-Rivas S, et al
    Evaluation of the clinical value of automatic online dose restoration for adaptive proton therapy of head and neck cancer.
    Radiother Oncol. 2022 Mar 25. pii: S0167-8140(22)00149.
    PubMed     Abstract available


  192. KARAVOLIA E, van Rijn-Dekker MI, Van den Bosch L, van den Hoek JGM, et al
    Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
    Radiother Oncol. 2022 Mar 15. pii: S0167-8140(22)00145.
    PubMed     Abstract available


  193. ZHOU X, Wang W, Zhou C, Zhu J, et al
    Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: An updated and expanded retrospective analysis.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00132.
    PubMed     Abstract available


  194. HUANG CC, Lai YR, Chiu WC, Fang FM, et al
    Concurrent chemoradiation therapy is associated with an accelerated risk of cardiovascular autonomic dysfunction in patients with nasopharyngeal carcinoma: A 9-year prospective follow-up study.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00129.
    PubMed     Abstract available


  195. CHOW R, Simone CB 2nd
    Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality.
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00112.
    PubMed    


  196. DAI D, Tian Q, Shui Y, Li J, et al
    Response to "Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality".
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00109.
    PubMed    


  197. NACHANKAR A, Musha A, Kubo N, Kawamura H, et al
    Dosimetric analysis of intraocular hemorrhage in nonsquamous head and neck cancers treated with carbon-ion radiotherapy.
    Radiother Oncol. 2022 Mar 4. pii: S0167-8140(22)00118.
    PubMed     Abstract available


  198. NORTH VS, Tran AQ, Kazim M
    Orbital adenoid cystic carcinoma arising from nasopharyngeal salivary gland origin.
    Radiother Oncol. 2022;168:104-105.
    PubMed    


  199. GORPHE P, Classe M, Ammari S, Garcia G, et al
    Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma.
    Radiother Oncol. 2022;168:40-45.
    PubMed     Abstract available


    February 2022
  200. BONOMO P, Desideri I, Mangoni M, Saieva C, et al
    Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial.
    Radiother Oncol. 2022 Feb 11. pii: S0167-8140(22)00091.
    PubMed     Abstract available


  201. SCANDURRA D, Meijer TWH, Free J, van den Hoek JGM, et al
    Evaluation of robustly optimised intensity modulated proton therapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Feb 5. pii: S0167-8140(22)00080.
    PubMed     Abstract available


  202. PAN D, Rong X, Zhu Y, Ng WT, et al
    A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis.
    Radiother Oncol. 2022 Feb 1. pii: S0167-8140(22)00060.
    PubMed     Abstract available


  203. PATIL S, Tawk B, Grosser M, Lohaus F, et al
    Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
    Radiother Oncol. 2022;167:300-307.
    PubMed     Abstract available


  204. TAMBAS M, van der Laan HP, Steenbakkers RJHM, Doyen J, et al
    Current practice in proton therapy delivery in adult cancer patients across Europe.
    Radiother Oncol. 2022;167:7-13.
    PubMed     Abstract available


  205. CHANG CW, Wang C, Lu CJ, Wang CW, et al
    Incidence and prognostic significance of extranodal extension in isolated nodal recurrence of oral squamous cell carcinoma.
    Radiother Oncol. 2022;167:81-88.
    PubMed     Abstract available


    January 2022
  206. SUN XS, Zhu MY, Wen DX, Luo DH, et al
    Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in local recurrence nasopharyngeal carcinoma patients.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00028.
    PubMed     Abstract available


  207. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Head and neck cancer diagnoses and faster treatment initiation during COVID-19: correspondence.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00026.
    PubMed    


  208. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence".
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00033.
    PubMed    


  209. CHATTERJEE S, Maulik S, Prasath S, Arun B, et al
    Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: Results of a prospective cohort study (Study ID CTRI/2017/11/010683).
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00024.
    PubMed     Abstract available


  210. ZECH HB, Berger J, Mansour WY, Nordquist L, et al
    Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00022.
    PubMed     Abstract available


  211. AL-MAMGANI A, Kessels R, Janssen T, Navran A, et al
    The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction.
    Radiother Oncol. 2022 Jan 20. pii: S0167-8140(22)00017.
    PubMed     Abstract available


  212. HE J, Qian L, Gao J
    Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00005.
    PubMed    


  213. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)"by He et al.
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00006.
    PubMed    


  214. DAI D, Tian Q, Shui Y, Li J, et al
    The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2022 Jan 8. pii: S0167-8140(22)00007.
    PubMed     Abstract available


  215. HUANG W, Zhang Q, Wu G, Chen P, et al
    Corrigendum to "DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients" [Radiother Oncol (2021) 164:146-154].
    Radiother Oncol. 2022 Jan 7. pii: S0167-8140(21)09059.
    PubMed    


  216. LIU T, Shen BW, Liu LT, Yang ZC, et al
    Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model.
    Radiother Oncol. 2022 Jan 5. pii: S0167-8140(21)09094.
    PubMed     Abstract available


  217. HONG CR, Buckley CD, Wong WW, Anekal PV, et al
    Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
    Radiother Oncol. 2022;166:162-170.
    PubMed     Abstract available


  218. FORNER LE, Dieleman FJ, Shaw RJ, Kanatas A, et al
    Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
    Radiother Oncol. 2022;166:137-144.
    PubMed     Abstract available


  219. WENNERBERG J, Gebre-Medhin M, Nilsson P, Brun E, et al
    Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity - The ARTSCAN 2 study.
    Radiother Oncol. 2022;166:26-32.
    PubMed     Abstract available


    December 2021
  220. GUO Q, Xiao N, Xu H, Zong J, et al
    Rationality of the international guideline's recommendation regarding selective coverage of level Ib in clinical target volume with nasopharyngeal carcinoma: Results from a real-world series.
    Radiother Oncol. 2021 Dec 29. pii: S0167-8140(21)09081.
    PubMed     Abstract available


  221. TANG SQ, Chen L, Li WF, Chan ATC, et al
    Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
    Radiother Oncol. 2021 Dec 28. pii: S0167-8140(21)09077.
    PubMed     Abstract available


  222. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis.
    Radiother Oncol. 2021 Dec 13. pii: S0167-8140(21)09049.
    PubMed     Abstract available


  223. MUSHA A, Hirai C, Kitada Y, Tsunoda A, et al
    Relationship between oral mucositis and the oral bacterial count in patients with head and neck cancer undergoing carbon ion radiotherapy: A prospective study.
    Radiother Oncol. 2021 Dec 10. pii: S0167-8140(21)09054.
    PubMed     Abstract available


  224. BEUKEMA JC, de Groot C, Plukker JTM, Vliegenthart R, et al
    Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study.
    Radiother Oncol. 2021 Dec 2. pii: S0167-8140(21)09025.
    PubMed     Abstract available


  225. CHOW R, Murdy K, Vaska M, Lee SL, et al
    Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis.
    Radiother Oncol. 2021;165:37-43.
    PubMed     Abstract available


  226. VORUGANTI IS, Poon I, Husain ZA, Bayley A, et al
    Stereotactic body radiotherapy for head and neck skin cancer.
    Radiother Oncol. 2021;165:1-7.
    PubMed     Abstract available


    November 2021
  227. KUTZ LM, Abel J, Schweizer D, Tribius S, et al
    Quality of life, HPV-status and phase angle predict survival in head and neck cancer patients under (chemo)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09004.
    PubMed     Abstract available


  228. JIN YN, Yang QQ, Li ZQ, Ou XQ, et al
    Development of a Web-based Prognostic Model to Quantify the Survival Benefit of Cumulative Cisplatin Dose during Concurrent Chemoradiotherapy in Childhood Nasopharyngeal Carcinoma.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09008.
    PubMed     Abstract available


  229. NISHIBUCHI I, Murakami Y, Kubo K, Imano N, et al
    Temporal Changes and Risk Factors for Esophageal Stenosis after Salvage Radiotherapy in Superficial Esophageal Cancer following Non-Curative Endoscopic Submucosal Dissection.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09007.
    PubMed     Abstract available


  230. PATEL V, Kwok J, Burke M, Urbano TG, et al
    Should the HPV positive oropharyngeal cancer patient be considered for a two-stage dental assessment for their radiation treatment?
    Radiother Oncol. 2021;164:232-235.
    PubMed     Abstract available


  231. GAN Y, Langendijk JA, Oldehinkel E, Scandurra D, et al
    A novel semi auto-segmentation method for accurate dose and NTCP evaluation in adaptive head and neck radiotherapy.
    Radiother Oncol. 2021;164:167-174.
    PubMed     Abstract available


  232. RUI M, Zhang X, Huang J, Wei D, et al
    The baseline oral microbiota predicts the response of locally advanced oral squamous cell carcinoma patients to induction chemotherapy: A prospective longitudinal study.
    Radiother Oncol. 2021;164:83-91.
    PubMed     Abstract available


    October 2021
  233. BROOKER RC, Antczak P, Liloglou T, Risk JM, et al
    Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy.
    Radiother Oncol. 2021;165:87-93.
    PubMed     Abstract available


  234. CHIN O, Yu E, O'Sullivan B, Su J, et al
    Prognostic Importance of Radiologic Extranodal Extension in Nasopharyngeal Carcinoma Treated in a Canadian Cohort.
    Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08785.
    PubMed     Abstract available


  235. ZHANG ZM, Zhao R, Bao Y, Zhou LX, et al
    A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08758.
    PubMed     Abstract available


  236. SHI Z, Zhu X, Ke S, Qiu H, et al
    Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08754.
    PubMed     Abstract available


  237. YAN A, Hanna A, Wilson TG, Deraniyagala R, et al
    Correlation between tumor voxel dose response matrix and tumor biomarker profile in patients with head and neck squamous cell carcinoma.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)08748.
    PubMed     Abstract available


  238. KANEHIRA T, van Kranen S, Jansen T, Hamming-Vrieze O, et al
    Comparisons of normal tissue complication probability models derived from planned and delivered dose for head and neck cancer patients.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)06738.
    PubMed     Abstract available


    September 2021
  239. HUANG W, Zhang Q, Wu G, Pian Chen P, et al
    DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2021 Sep 27. pii: S0167-8140(21)06739.
    PubMed     Abstract available


  240. WAGENAAR D, Schuit E, van der Schaaf A, Langendijk JA, et al
    Can the mean linear energy transfer of organs be directly related to patient toxicities for current head and neck cancer intensity-modulated proton therapy practice?
    Radiother Oncol. 2021 Sep 14. pii: S0167-8140(21)06723.
    PubMed     Abstract available


  241. WANG X, Hobbs B, Gandhi SJ, Muijs CT, et al
    Current Status and Application of Proton Therapy for Esophageal Cancer.
    Radiother Oncol. 2021 Sep 14. pii: S0167-8140(21)06724.
    PubMed     Abstract available


  242. CHOW JCH, Lee A, Bao KKH, Cheung KM, et al
    Cranial neuropathies in advanced nasopharyngeal carcinoma: Neurological recovery after modern radiotherapy and systemic chemotherapy.
    Radiother Oncol. 2021 Sep 7. pii: S0167-8140(21)06716.
    PubMed     Abstract available


    August 2021
  243. KROESE TE, Jairam J, Ruurda JP, Lin SH, et al
    Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: incidence and external validation of a prediction model.
    Radiother Oncol. 2021 Aug 25. pii: S0167-8140(21)06703.
    PubMed     Abstract available


  244. LIU T, Liu LT, Lin JY, Shen BW, et al
    Management of Suboptimal Response to Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Re-induction Therapy or Direct to Radiotherapy?
    Radiother Oncol. 2021 Aug 25. pii: S0167-8140(21)06704.
    PubMed     Abstract available


  245. MUSHA A, Shimada H, Kubo N, Kawamura H, et al
    Clinical features and dosimetric evaluation of carbon ion radiation-induced osteoradionecrosis of mandible in head and neck tumors.
    Radiother Oncol. 2021;161:205-210.
    PubMed     Abstract available


  246. WENTZEL A, Luciani T, van Dijk LV, Taku N, et al
    Precision association of lymphatic disease spread with radiation-associated toxicity in oropharyngeal squamous carcinomas.
    Radiother Oncol. 2021;161:152-158.
    PubMed     Abstract available


  247. N B P, Ravi KS, Durgapal P
    Discovery of new salivary gland - A substantial histological analysis.
    Radiother Oncol. 2021;161:92-94.
    PubMed     Abstract available


  248. GREGOIRE V, Bauwens L
    Reply to sanguineti regarding the manuscript untitled "Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma".
    Radiother Oncol. 2021;161:253.
    PubMed    


  249. SANGUINETI G
    Re: Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. Radiother Oncol, 2021. 157: p. 122-129.
    Radiother Oncol. 2021;161:251-252.
    PubMed    


  250. SHARABIANI M, Clementel E, Andratschke N, Collette L, et al
    Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis.
    Radiother Oncol. 2021;161:35-39.
    PubMed     Abstract available


    July 2021
  251. WANG XY, Zhu SY, Wu WJ, Li HJ, et al
    Corrigendum to "Extent of paranasal sinus involvement and its prognostic value in nasopharyngeal carcinoma: Proposed modification in the current UICC/AJCC staging system" [Radiother Oncol 160 (2021) 221-227].
    Radiother Oncol. 2021 Jul 31. pii: S0167-8140(21)06644.
    PubMed    


  252. YANG G, Feng D, Li F, Luo B, et al
    A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma.
    Radiother Oncol. 2021 Jul 31. pii: S0167-8140(21)06667.
    PubMed     Abstract available


  253. PARSAI S, Lei J Qiu R, Qi P, Sedor G, et al
    In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation.
    Radiother Oncol. 2021 Jul 29. pii: S0167-8140(21)06666.
    PubMed     Abstract available


  254. AL-MAMGANI A, Kessels R, Navran A, Hamming-Vrieze O, et al
    Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes.
    Radiother Oncol. 2021 Jul 23. pii: S0167-8140(21)06659.
    PubMed     Abstract available


  255. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on "Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)" by Baiocchi et al.
    Radiother Oncol. 2021 Jul 15. pii: S0167-8140(21)06639.
    PubMed    


  256. MUNARETTO TIMM BAIOCCHI J, Fischer-Sgrott F, Baiocchi Neto G
    Comment on "Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2021 Jul 15. pii: S0167-8140(21)06642.
    PubMed    


  257. JO YY, Yu J, Song KJ, Jang JY, et al
    Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: a retrospective study.
    Radiother Oncol. 2021 Jul 12. pii: S0167-8140(21)06643.
    PubMed     Abstract available


  258. BOEKHOFF MR, Defize IL, Borggreve AS, van Hillegersberg R, et al
    An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients.
    Radiother Oncol. 2021 Jul 5. pii: S0167-8140(21)06626.
    PubMed     Abstract available


  259. VAN DER LAAN HP, van der Schaaf A, Van den Bosch L, Korevaar EW, et al
    Quality of life and toxicity guided treatment plan optimisation for head and neck cancer.
    Radiother Oncol. 2021 Jul 5. pii: S0167-8140(21)06623.
    PubMed     Abstract available


  260. CARSUZAA F, Lapeyre M, Gregoire V, Maingon P, et al
    Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus.
    Radiother Oncol. 2021;160:140-147.
    PubMed     Abstract available


  261. CHEN X, Sun S, Bai N, Han K, et al
    A deep learning-based auto-segmentation system for organs-at-risk on whole-body computed tomography images for radiation therapy.
    Radiother Oncol. 2021;160:175-184.
    PubMed     Abstract available


  262. SAMBASIVAN K, Sassoon I, Thavaraj S, Kennedy R, et al
    TNM 8 staging is a better prognosticator than TNM 7 for patients with locally advanced oral cavity squamous cell carcinoma treated with surgery and post-operative radiotherapy.
    Radiother Oncol. 2021;160:54-60.
    PubMed     Abstract available


  263. CAO J, Zhang X, Jiang B, Chen J, et al
    Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia.
    Radiother Oncol. 2021;160:32-39.
    PubMed     Abstract available


    June 2021
  264. SUN XS, Xie SY, Luo DH, Liu LT, et al
    Impact of smoking on survival in nasopharyngeal carcinoma: A cohort study with 23,325 patients diagnosed from 1990 to 2016.
    Radiother Oncol. 2021 Jun 25. pii: S0167-8140(21)06612.
    PubMed     Abstract available


  265. DONNELLY O, Goranova R, Nugent M
    Letter to the editor regarding the article "Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)" by Robijns et al. Radiat Oncol. 2021.
    Radiother Oncol. 2021 Jun 15. pii: S0167-8140(21)06579.
    PubMed    


  266. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Letter to the editor by Donnelly et al. regarding the article "Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2021 Jun 10. pii: S0167-8140(21)06581.
    PubMed    


  267. JIN YN, Yao JJ, You YF, Cao HJ, et al
    Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study.
    Radiother Oncol. 2021 Jun 8. pii: S0167-8140(21)06575.
    PubMed     Abstract available


  268. DE BREE R, Swartz JE, Bril S, Chargi N, et al
    Skeletal muscle mass measurements using head and neck CT imaging in head and neck cancer patients.
    Radiother Oncol. 2021 Jun 6. pii: S0167-8140(21)06573.
    PubMed    


  269. LALONDE A, Bobic M, Winey B, Verburg J, et al
    Anatomic changes in head and neck intensity-modulated proton therapy: Comparison between robust optimization and online adaptation.
    Radiother Oncol. 2021;159:39-47.
    PubMed     Abstract available


    May 2021
  270. JIANG C, Gong B, Gao H, Zhang T, et al
    Correlation analysis of neck node levels in 960 cases of Nasopharyngeal carcinoma (NPC).
    Radiother Oncol. 2021 May 24. pii: S0167-8140(21)06258.
    PubMed     Abstract available


  271. BOEKHOFF MR, Defize IL, Borggreve AS, van Hillegersberg R, et al
    CTV-to-PTV margin assessment for esophageal cancer radiotherapy based on an accumulated dose analysis.
    Radiother Oncol. 2021 May 13. pii: S0167-8140(21)06241.
    PubMed     Abstract available


  272. WANG XY, Zhu SY, Wu WJ, Li HJ, et al
    Extent of Paranasal Sinus Involvement and its Prognostic Value in Nasopharyngeal Carcinoma: Proposed Modification in the Current UICC/AJCC staging system.
    Radiother Oncol. 2021 May 10. pii: S0167-8140(21)06224.
    PubMed     Abstract available


  273. SUN Z, Hu S, Xue Q, Jin L, et al
    Can 3D pseudo-continuous arterial spin labeling perfusion imaging be applied to predict early response to chemoradiotherapy in patients with advanced nasopharyngeal carcinoma?
    Radiother Oncol. 2021 May 2. pii: S0167-8140(21)06214.
    PubMed     Abstract available


  274. CIECIOR W, Ebert N, Borgeaud N, Thames HD, et al
    Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models.
    Radiother Oncol. 2021;158:262-267.
    PubMed     Abstract available


  275. LAI Y, Zeng X, Zhou K, Zhou X, et al
    End to end intussusception anastomosis decreases the risk of anastomotic leakage after neoadjvant chemoradiation and McKeown oesophagectomy.
    Radiother Oncol. 2021;158:285-292.
    PubMed     Abstract available


  276. HAGUE C, McPartlin A, Lee LW, Hughes C, et al
    An evaluation of MR based deep learning auto-contouring for planning head and neck radiotherapy.
    Radiother Oncol. 2021;158:112-117.
    PubMed     Abstract available


  277. LEE J, Liu SH, Chen JC, Leu YS, et al
    Progressive muscle loss is an independent predictor for survival in locally advanced oral cavity cancer: A longitudinal study.
    Radiother Oncol. 2021;158:83-89.
    PubMed     Abstract available


  278. ZHAO L, Chen S, Chen S, Pang Y, et al
    (68)Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer.
    Radiother Oncol. 2021;158:55-61.
    PubMed     Abstract available


    April 2021
  279. TAMBAS M, der Laan HPV, Rutgers W, van den Hoek JGM, et al
    Development of advanced preselection tools to reduce redundant plan comparisons in model-based selection of head and neck cancer patients for proton therapy.
    Radiother Oncol. 2021 Apr 20. pii: S0167-8140(21)06194.
    PubMed     Abstract available


  280. VAN DER LAAN HP, Van den Bosch L, Schuit E, Steenbakkers RJHM, et al
    aImpact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer.
    Radiother Oncol. 2021 Apr 20. pii: S0167-8140(21)06193.
    PubMed     Abstract available


  281. ELICIN O, Koller Brolese E, Bojaxhiu B, Sermaxhaj B, et al
    The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer.
    Radiother Oncol. 2021 Apr 10. pii: S0167-8140(21)06185.
    PubMed     Abstract available


  282. ESTEBAN B, Pierre P, Camille S, Pascal P, et al
    Influence of postoperative radiotherapy target volumes in unilateral head and neck carcinoma of unknown primary: a multicentric study using propensity score.
    Radiother Oncol. 2021 Apr 9. pii: S0167-8140(21)06183.
    PubMed     Abstract available


  283. LU ZJ, Liu LT, Sun XS, Guo SS, et al
    Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06175.
    PubMed     Abstract available


  284. YAN JJ, Guo SS, Lin DF, Liu LT, et al
    Development and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06180.
    PubMed     Abstract available


  285. QIU Y, Guo Z, Lin X, Li J, et al
    Standard radiotherapy for patients with nasopharyngeal carcinoma results in progressive tract-specific brain white matter alterations: A one-year follow-up via diffusion tensor imaging.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06179.
    PubMed     Abstract available


  286. ZHANG Y, Feng W, Gao LT, Cai XW, et al
    Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma.
    Radiother Oncol. 2021 Apr 1. pii: S0167-8140(21)06171.
    PubMed     Abstract available


  287. WONG ET, Huang SH, O'Sullivan B, Persaud V, et al
    Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy.
    Radiother Oncol. 2021;157:255-262.
    PubMed     Abstract available


  288. JENSEN GL, Axelrud G, Fink D, Hammonds K, et al
    Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT.
    Radiother Oncol. 2021;157:234-240.
    PubMed     Abstract available


  289. BAUWENS L, Baltres A, Fiani DJ, Zrounba P, et al
    Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2021;157:122-129.
    PubMed     Abstract available


  290. GUNN L, Gilbert J, Nenclares P, Soliman H, et al
    Taste dysfunction following radiotherapy to the head and neck: A systematic review.
    Radiother Oncol. 2021;157:130-140.
    PubMed     Abstract available


  291. MEN K, Chen X, Yang B, Zhu J, et al
    Automatic segmentation of three clinical target volumes in radiotherapy using lifelong learning.
    Radiother Oncol. 2021;157:1-7.
    PubMed     Abstract available


  292. STIEB S, Mohamed ASR, He R, Zhu LL, et al
    Development and validation of a contouring guideline for the taste bud bearing tongue mucosa.
    Radiother Oncol. 2021;157:63-69.
    PubMed     Abstract available


    March 2021
  293. PATEL S, Patel N, Sassoon I, Patel V, et al
    The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws.
    Radiother Oncol. 2021;156:209-216.
    PubMed     Abstract available


  294. AKBABA S, Ruhle A, Rothhaar S, Zamboglou C, et al
    Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - Results from a large multicenter analysis.
    Radiother Oncol. 2021;156:266-274.
    PubMed     Abstract available


  295. THOMAS M, Mortensen HR, Hoffmann L, Moller DS, et al
    Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer.
    Radiother Oncol. 2021;156:102-112.
    PubMed     Abstract available


  296. HOSNI A, Huang SH, Xu W, Su J, et al
    Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma.
    Radiother Oncol. 2021;156:95-101.
    PubMed     Abstract available


    February 2021
  297. DIETRICH A, Andreeff M, Koi L, Bergmann R, et al
    Radiotherapy enhances uptake and efficacy of (90)Y-cetuximab: A preclinical trial.
    Radiother Oncol. 2021;155:285-292.
    PubMed     Abstract available


  298. MICHAELIDOU A, Adjogatse D, Suh Y, Pike L, et al
    18F-FDG-PET in guided dose-painting with intensity modulated radiotherapy in oropharyngeal tumours: A phase I study (FiGaRO).
    Radiother Oncol. 2021;155:261-268.
    PubMed     Abstract available


  299. ROSEN BS, Wilkie JR, Sun Y, Ibrahim M, et al
    CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Radiother Oncol. 2021;155:174-181.
    PubMed     Abstract available


    January 2021
  300. HOSNI A, Chiu K, Huang SH, Xu W, et al
    Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach.
    Radiother Oncol. 2021;154:70-75.
    PubMed     Abstract available


  301. NARAYAN RK, Kumari C, Panchal P, Ghosh SK, et al
    A macroscopic salivary gland and a potential organ or simply tubarial sero-mucinous glands?
    Radiother Oncol. 2021;154:324-325.
    PubMed    


  302. YAN D, Chen S, Krauss DJ, Deraniyagala R, et al
    Inter/intra-tumoral dose response variations assessed using FDG-PET/CT feedback images: Impact on tumor control and treatment dose prescription.
    Radiother Oncol. 2021;154:235-242.
    PubMed     Abstract available


  303. VALSTAR MH, de Bakker BS, Steenbakkers RJHM, de Jong KH, et al
    The tubarial salivary glands: A potential new organ at risk for radiotherapy.
    Radiother Oncol. 2021;154:292-298.
    PubMed     Abstract available


  304. WAGENAAR D, Kierkels RGJ, van der Schaaf A, Meijers A, et al
    Head and neck IMPT probabilistic dose accumulation: Feasibility of a 2 mm setup uncertainty setting.
    Radiother Oncol. 2021;154:45-52.
    PubMed     Abstract available


  305. QIU X, Xu T, Li M, Fei Z, et al
    Response to Chai' letter: What caused the difference in prognosis among different physicians?
    Radiother Oncol. 2021;154:e20-e21.
    PubMed    


    December 2020
  306. VAN DER VEEN J, Willems S, Bollen H, Maes F, et al
    Deep learning for elective neck delineation: More consistent and time efficient.
    Radiother Oncol. 2020;153:180-188.
    PubMed     Abstract available


    October 2020
  307. LIU WC, Liu HE, Kao YW, Qin L, et al
    Definitive radiotherapy or surgery for early oral squamous cell carcinoma in old and very old patients: A propensity-score-matched, nationwide, population-based cohort study.
    Radiother Oncol. 2020;151:214-221.
    PubMed     Abstract available


  308. HAMILTON SN, Urban R, Liu A, Chau N, et al
    Population-based outcomes by immunosuppressed status in patients undergoing radiotherapy for oropharyngeal cancer.
    Radiother Oncol. 2020;151:110-117.
    PubMed     Abstract available


  309. LAI TY, Yeh CM, Hu YW, Liu CJ, et al
    Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy.
    Radiother Oncol. 2020;151:190-199.
    PubMed     Abstract available


  310. LERCH S, Berthold S, Ziemann F, Dreffke K, et al
    HPV-positive HNSCC cell lines show strongly enhanced radiosensitivity after photon but not after carbon ion irradiation.
    Radiother Oncol. 2020;151:134-140.
    PubMed     Abstract available


  311. SHARMA MB, Jensen K, Urbak SF, Funding M, et al
    A multidimensional cohort study of late toxicity after intensity modulated radiotherapy for sinonasal cancer.
    Radiother Oncol. 2020;151:58-65.
    PubMed     Abstract available


  312. ENGESETH GM, Stieb S, Mohamed ASR, He R, et al
    Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers.
    Radiother Oncol. 2020;151:119-125.
    PubMed     Abstract available


  313. ANAKOTTA RM, van der Laan HP, Visser S, Ribeiro CO, et al
    Weekly robustness evaluation of intensity-modulated proton therapy for oesophageal cancer.
    Radiother Oncol. 2020;151:66-72.
    PubMed     Abstract available


    August 2020
  314. BEUKEMA JC, Kawaguchi Y, Sijtsema NM, Zhai TT, et al
    Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?
    Radiother Oncol. 2020;149:222-227.
    PubMed     Abstract available


  315. GOTTGENS EL, Bussink J, Ansems M, Hammond EM, et al
    AKT inhibition as a strategy for targeting hypoxic HPV-positive HNSCC.
    Radiother Oncol. 2020;149:1-7.
    PubMed     Abstract available


    July 2020
  316. JOURNY N, Schonfeld SJ, Hauptmann M, Roberti S, et al
    Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer.
    Radiother Oncol. 2020 Jul 14. pii: S0167-8140(20)30415.
    PubMed     Abstract available


  317. WENTZEL A, Hanula P, van Dijk LV, Elgohari B, et al
    Precision toxicity correlates of tumor spatial proximity to organs at risk in cancer patients receiving intensity-modulated radiotherapy.
    Radiother Oncol. 2020;148:245-251.
    PubMed     Abstract available


  318. VAN DEN BOSCH L, Schuit E, van der Laan HP, Reitsma JB, et al
    Key challenges in normal tissue complication probability model development and validation: towards a comprehensive strategy.
    Radiother Oncol. 2020;148:151-156.
    PubMed     Abstract available


  319. KAANDERS JHAM, van den Bosch S, Dijkema T, Al-Mamgani A, et al
    Advances in cancer imaging require renewed radiotherapy dose and target volume concepts.
    Radiother Oncol. 2020;148:140-142.
    PubMed     Abstract available


  320. GRANT SR, Hutcheson KA, Ye R, Garden AS, et al
    Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer.
    Radiother Oncol. 2020;148:133-139.
    PubMed     Abstract available


  321. SAKSO M, Jensen K, Andersen M, Hansen CR, et al
    DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx,
    Radiother Oncol. 2020;148:65-72.
    PubMed     Abstract available


  322. WILKIE JR, Mierzwa ML, Casper KA, Mayo CS, et al
    Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics.
    Radiother Oncol. 2020;148:30-37.
    PubMed     Abstract available


    June 2020
  323. VAN DER HEIJDEN M, Essers PBM, Verhagen CVM, Willems SM, et al
    Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy.
    Radiother Oncol. 2020;147:186-194.
    PubMed     Abstract available


  324. MANZAR GS, Lester SC, Routman DM, Harmsen WS, et al
    Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.
    Radiother Oncol. 2020;147:64-74.
    PubMed     Abstract available


  325. HANSEN CR, Bertelsen A, Zukauskaite R, Johnsen L, et al
    Prediction of radiation-induced mucositis of H&N cancer patients based on a large patient cohort.
    Radiother Oncol. 2020;147:15-21.
    PubMed     Abstract available


    April 2020
  326. VISCHIONI B, Dhanireddy B, Severo C, Bonora M, et al
    Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO.
    Radiother Oncol. 2020;145:172-177.
    PubMed     Abstract available


  327. DE FELICE F, Bird T, Michaelidou A, Thavaraj S, et al
    Radical (chemo)radiotherapy in oropharyngeal squamous cell carcinoma: Comparison of TNM 7th and 8th staging systems.
    Radiother Oncol. 2020;145:146-153.
    PubMed     Abstract available


  328. NG SP, Bahig H, Jethanandani A, Pollard C, et al
    Lymphopenia during radiotherapy in patients with oropharyngeal cancer.
    Radiother Oncol. 2020;145:95-100.
    PubMed     Abstract available


    March 2020
  329. WONG J, Fong A, McVicar N, Smith S, et al
    Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning.
    Radiother Oncol. 2020;144:152-158.
    PubMed     Abstract available


  330. HUANG SH, O'Sullivan B, Su J, Bartlett E, et al
    Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification.
    Radiother Oncol. 2020;144:13-22.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.